Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites

Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and developm...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and disposition Vol. 38; no. 10; pp. 1900 - 1905
Main Authors Wang, Wendy WeiWei, Khetani, Salman R., Krzyzewski, Stacy, Duignan, David B., Obach, R. Scott
Format Journal Article
LanguageEnglish
Published Bethesda, MD Elsevier Inc 01.10.2010
American Society for Pharmacology and Experimental Therapeutics
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and development of new drugs. In this study, a novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites. Twenty-seven compounds of diverse chemical structure and subject to a range of drug biotransformation reactions were assessed for metabolite profiles in the micropatterned coculture system using pooled cryopreserved human hepatocytes. The ability of this system to generate metabolites that are >10% of dose in excreta or >10% of total drug-related material in circulation was assessed and compared to previously reported data obtained in human hepatocyte suspensions, liver S-9 fraction, and liver microsomes. The micropatterned coculture system was incubated for up to 7 days without a change in medium, which offered an ability to generate metabolites for slowly metabolized compounds. The micropatterned coculture system generated 82% of the excretory metabolites that exceed 10% of dose and 75% of the circulating metabolites that exceed 10% of total circulating drug-related material, exceeds the performance of hepatocyte suspension incubations and other in vitro systems. Phase 1 and phase 2 metabolites were generated, as well as metabolites that arise via two or more sequential reactions. These results suggest that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vivo metabolites.
AbstractList Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and development of new drugs. In this study, a novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites. Twenty-seven compounds of diverse chemical structure and subject to a range of drug biotransformation reactions were assessed for metabolite profiles in the micropatterned coculture system using pooled cryopreserved human hepatocytes. The ability of this system to generate metabolites that are >10% of dose in excreta or >10% of total drug-related material in circulation was assessed and compared to previously reported data obtained in human hepatocyte suspensions, liver S-9 fraction, and liver microsomes. The micropatterned coculture system was incubated for up to 7 days without a change in medium, which offered an ability to generate metabolites for slowly metabolized compounds. The micropatterned coculture system generated 82% of the excretory metabolites that exceed 10% of dose and 75% of the circulating metabolites that exceed 10% of total circulating drug-related material, exceeds the performance of hepatocyte suspension incubations and other in vitro systems. Phase 1 and phase 2 metabolites were generated, as well as metabolites that arise via two or more sequential reactions. These results suggest that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vivo metabolites.
Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and development of new drugs. In this study, a novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites. Twenty-seven compounds of diverse chemical structure and subject to a range of drug biotransformation reactions were assessed for metabolite profiles in the micropatterned coculture system using pooled cryopreserved human hepatocytes. The ability of this system to generate metabolites that are >10% of dose in excreta or >10% of total drug-related material in circulation was assessed and compared to previously reported data obtained in human hepatocyte suspensions, liver S-9 fraction, and liver microsomes. The micropatterned coculture system was incubated for up to 7 days without a change in medium, which offered an ability to generate metabolites for slowly metabolized compounds. The micropatterned coculture system generated 82% of the excretory metabolites that exceed 10% of dose and 75% of the circulating metabolites that exceed 10% of total circulating drug-related material, exceeds the performance of hepatocyte suspension incubations and other in vitro systems. Phase 1 and phase 2 metabolites were generated, as well as metabolites that arise via two or more sequential reactions. These results suggest that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vivo metabolites.Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety. Predicting which drug metabolites will be quantitatively predominant in humans has become increasingly important in the research and development of new drugs. In this study, a novel micropatterned hepatocyte coculture system was evaluated for its ability to generate human in vivo metabolites. Twenty-seven compounds of diverse chemical structure and subject to a range of drug biotransformation reactions were assessed for metabolite profiles in the micropatterned coculture system using pooled cryopreserved human hepatocytes. The ability of this system to generate metabolites that are >10% of dose in excreta or >10% of total drug-related material in circulation was assessed and compared to previously reported data obtained in human hepatocyte suspensions, liver S-9 fraction, and liver microsomes. The micropatterned coculture system was incubated for up to 7 days without a change in medium, which offered an ability to generate metabolites for slowly metabolized compounds. The micropatterned coculture system generated 82% of the excretory metabolites that exceed 10% of dose and 75% of the circulating metabolites that exceed 10% of total circulating drug-related material, exceeds the performance of hepatocyte suspension incubations and other in vitro systems. Phase 1 and phase 2 metabolites were generated, as well as metabolites that arise via two or more sequential reactions. These results suggest that this in vitro system offers the highest performance among in vitro metabolism systems to predict major human in vivo metabolites.
Author Khetani, Salman R.
Duignan, David B.
Krzyzewski, Stacy
Wang, Wendy WeiWei
Obach, R. Scott
Author_xml – sequence: 1
  givenname: Wendy WeiWei
  surname: Wang
  fullname: Wang, Wendy WeiWei
– sequence: 2
  givenname: Salman R.
  surname: Khetani
  fullname: Khetani, Salman R.
– sequence: 3
  givenname: Stacy
  surname: Krzyzewski
  fullname: Krzyzewski, Stacy
– sequence: 4
  givenname: David B.
  surname: Duignan
  fullname: Duignan, David B.
– sequence: 5
  givenname: R. Scott
  surname: Obach
  fullname: Obach, R. Scott
  email: r.scott.obach@pfizer.com
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23276863$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20595376$$D View this record in MEDLINE/PubMed
BookMark eNp1kUFv1DAQRi1URLeFK0fkC-KUxY7jxD5WS-kidcUBkLhFE3tSuUrsxXYq9sB_x9UuICH1NCPNe3P4vgty5oNHQl5ztua8bt7b2ZaFrZloVNc-Iysua14xpr-fkVUZrNJStufkIqV7xnjTCP2CnNdMaim6dkV-XaWEKc3oMw0jBbpzJoY95IzRo6VbLHswh4x0E8wy5SUi_XJIGWeaA71BjxHKcQf3IdLtMoOn1z9NxBzigYK3dONi8SA7f0c_xOWO7jDDECaXMb0kz0eYEr46zUvy7eP11822uv1882lzdVsZ0epcobJaWOgE6kZIy2uuOyM7qYHXjIvB1FZwo5TmSlgz6m4YxlGjYSNroFVKXJJ3x7_7GH4smHI_u2RwmsBjWFLfSclbUWtRyDcnchlmtP0-uhniof-TWAHengBIBqYxgjcu_eNE3bWqfXy0PnIlzpQijn8RzvrH6vpSXVlYf6yuCM1_gnG5xBZ8juCmpzV11LDk9-Aw9sk49Aati2hyb4N7Sv0NuDew6A
CODEN DMDSAI
CitedBy_id crossref_primary_10_1007_s00204_019_02585_5
crossref_primary_10_1039_C9LC00857H
crossref_primary_10_3109_00498254_2014_956158
crossref_primary_10_1124_jpet_112_195834
crossref_primary_10_1039_C7IB00027H
crossref_primary_10_1016_j_biotechadv_2013_03_007
crossref_primary_10_1016_j_tiv_2018_01_015
crossref_primary_10_1155_2017_9176937
crossref_primary_10_1124_dmd_124_001732
crossref_primary_10_1124_dmd_113_053397
crossref_primary_10_1126_scitranslmed_3005975
crossref_primary_10_3390_toxics10100566
crossref_primary_10_1093_toxsci_kfaa094
crossref_primary_10_1093_toxsci_kfv048
crossref_primary_10_1016_j_biotechadv_2014_01_003
crossref_primary_10_1124_dmd_114_057901
crossref_primary_10_3727_105221619X15638857793317
crossref_primary_10_1080_03602532_2016_1191843
crossref_primary_10_3389_fcell_2021_626805
crossref_primary_10_1002_hep_27621
crossref_primary_10_3389_fbioe_2021_730008
crossref_primary_10_1016_j_heliyon_2017_e00354
crossref_primary_10_1055_a_1981_5944
crossref_primary_10_3389_fmicb_2022_999366
crossref_primary_10_1124_dmd_118_081182
crossref_primary_10_1124_dmd_118_084293
crossref_primary_10_1146_annurev_virology_031413_085437
crossref_primary_10_1002_adhm_202202302
crossref_primary_10_1093_toxsci_kfx059
crossref_primary_10_1021_acs_chemrestox_8b00054
crossref_primary_10_1177_2211068214566939
crossref_primary_10_1039_C6LC01554A
crossref_primary_10_2133_dmpk_DMPK_13_RG_105
crossref_primary_10_3109_00498254_2013_855836
crossref_primary_10_1016_j_cmet_2019_02_003
crossref_primary_10_1186_s12936_018_2198_4
crossref_primary_10_1080_17460441_2023_2238606
crossref_primary_10_3233_JCB_179012
crossref_primary_10_4155_bio_2016_0094
crossref_primary_10_1517_17460441_2012_651122
crossref_primary_10_1289_EHP12006
crossref_primary_10_1098_rstb_2017_0225
crossref_primary_10_1038_nprot_2015_128
crossref_primary_10_1016_j_bbrep_2017_04_004
crossref_primary_10_1517_17425255_2014_876006
crossref_primary_10_1016_j_tibtech_2016_08_001
crossref_primary_10_1093_toxsci_kfs326
crossref_primary_10_1002_jbm_a_36293
crossref_primary_10_1007_s11095_024_03787_y
crossref_primary_10_1016_j_jcmgh_2017_11_012
crossref_primary_10_1021_acs_molpharmaceut_6b00396
crossref_primary_10_1124_dmd_115_066688
crossref_primary_10_1124_dmd_123_001638
crossref_primary_10_1038_scibx_2011_843
crossref_primary_10_1063_5_0051765
crossref_primary_10_1039_C2TX20051A
crossref_primary_10_2174_1574888X17666220614160957
crossref_primary_10_1002_em_22077
crossref_primary_10_1093_toxsci_kfab018
crossref_primary_10_1124_dmd_113_055897
crossref_primary_10_3109_00498254_2011_621985
crossref_primary_10_1517_17460441_2015_1032241
crossref_primary_10_1016_j_dmpk_2025_101478
crossref_primary_10_1124_dmd_118_083295
crossref_primary_10_1124_dmd_112_046425
crossref_primary_10_3390_v15010158
crossref_primary_10_1016_j_jcmgh_2017_11_007
crossref_primary_10_1016_j_xphs_2018_03_001
crossref_primary_10_1002_biot_201800347
crossref_primary_10_1124_dmd_115_066431
crossref_primary_10_1089_nat_2013_0456
crossref_primary_10_1124_dmd_118_082867
crossref_primary_10_1080_03602532_2021_1922435
crossref_primary_10_1002_cptx_23
crossref_primary_10_1124_dmd_114_057026
crossref_primary_10_1016_j_biotechadv_2013_10_006
crossref_primary_10_1124_dmd_115_066027
crossref_primary_10_3109_00498254_2011_562330
crossref_primary_10_2174_1872312814666201202112610
crossref_primary_10_1002_cpt_2691
crossref_primary_10_1016_j_drudis_2011_02_012
crossref_primary_10_1016_j_chom_2013_06_005
crossref_primary_10_1021_acs_chemrestox_6b00150
crossref_primary_10_1177_1535370217708976
crossref_primary_10_1124_pharmrev_120_000238
crossref_primary_10_1080_03602532_2024_2370330
crossref_primary_10_1016_j_tiv_2014_05_007
crossref_primary_10_1517_17425255_2012_693161
crossref_primary_10_1124_dmd_115_067348
crossref_primary_10_1124_dmd_115_065326
crossref_primary_10_12688_openreseurope_13335_1
crossref_primary_10_1124_dmd_113_055947
crossref_primary_10_1517_17425255_2012_693159
crossref_primary_10_3389_fphar_2019_01093
crossref_primary_10_1021_acs_jmedchem_9b01840
crossref_primary_10_3389_ftox_2023_1051483
crossref_primary_10_1016_j_apsb_2022_03_009
crossref_primary_10_3109_10408444_2012_682115
crossref_primary_10_1002_jbt_21469
crossref_primary_10_1016_j_tiv_2018_01_023
crossref_primary_10_1177_1535370214531872
crossref_primary_10_1089_adt_2013_525
crossref_primary_10_1124_dmd_115_063495
crossref_primary_10_1016_j_copbio_2011_05_512
crossref_primary_10_1080_00498254_2017_1395927
crossref_primary_10_1002_jat_3091
crossref_primary_10_1124_dmd_120_000013
crossref_primary_10_1124_dmd_113_055715
crossref_primary_10_1124_dmd_113_053397fullarticlecorrection
crossref_primary_10_1124_dmd_115_067173
crossref_primary_10_1002_jat_3805
crossref_primary_10_1124_dmd_115_067850
Cites_doi 10.1021/tx8004357
10.1021/tx900124j
10.1021/tx800415j
10.4155/bio.09.98
10.1517/17425255.4.10.1279
10.1021/tx8004086
10.1080/03602530601093489
10.1016/S0090-9556(24)15179-3
10.1038/nbt1361
ContentType Journal Article
Copyright 2010 American Society for Pharmacology and Experimental Therapeutics
2015 INIST-CNRS
Copyright_xml – notice: 2010 American Society for Pharmacology and Experimental Therapeutics
– notice: 2015 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1124/dmd.110.034876
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-009X
EndPage 1905
ExternalDocumentID 20595376
23276863
10_1124_dmd_110_034876
S0090955624025157
Genre Journal Article
GroupedDBID ---
.GJ
0R~
18M
2WC
4.4
53G
5GY
5RE
5VS
AAXUO
ABJNI
ABSQV
ACGFO
ACGFS
ACIWK
ACPRK
ADBBV
AENEX
AERNN
AFFNX
AFOSN
AFRAH
AI.
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
F9R
FDB
GX1
H13
HZ~
IH2
INIJC
KQ8
LSO
M41
O9-
OK1
P2P
R0Z
RHI
ROL
RPT
SJN
TR2
VH1
W8F
WH7
WOQ
YCJ
YHG
ZGI
ZXP
~KM
AALRI
AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c369t-e8d93da73e9435d12197c5759a12013bc2d31c889183dcf97bbff9ec0f04a6883
ISSN 0090-9556
1521-009X
IngestDate Thu Jul 10 18:09:28 EDT 2025
Mon Jul 21 05:43:51 EDT 2025
Mon Jul 21 09:16:56 EDT 2025
Tue Jul 01 05:28:21 EDT 2025
Thu Apr 24 23:03:56 EDT 2025
Sun Apr 06 06:53:03 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords CP-122721
HCM
CP-533536
ADME
CP-547632
CP-690550
CJ-13610
HPLC
Human
Drug
Evaluation
Mixed cell culture
Hepatocyte
Digestive system
Metabolite
Liver
In vitro
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c369t-e8d93da73e9435d12197c5759a12013bc2d31c889183dcf97bbff9ec0f04a6883
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 20595376
PQID 755163293
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_755163293
pubmed_primary_20595376
pascalfrancis_primary_23276863
crossref_primary_10_1124_dmd_110_034876
crossref_citationtrail_10_1124_dmd_110_034876
elsevier_sciencedirect_doi_10_1124_dmd_110_034876
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-10-01
PublicationDateYYYYMMDD 2010-10-01
PublicationDate_xml – month: 10
  year: 2010
  text: 2010-10-01
  day: 01
PublicationDecade 2010
PublicationPlace Bethesda, MD
PublicationPlace_xml – name: Bethesda, MD
– name: United States
PublicationTitle Drug metabolism and disposition
PublicationTitleAlternate Drug Metab Dispos
PublicationYear 2010
Publisher Elsevier Inc
American Society for Pharmacology and Experimental Therapeutics
Publisher_xml – name: Elsevier Inc
– name: American Society for Pharmacology and Experimental Therapeutics
References Smith, Obach (bib10) 2009; 22
Atrakchi (bib2) 2009; 22
Hewitt, Lechón, Houston, Hallifax, Brown, Maurel, Kenna, Gustavsson, Lohmann, Skonberg (bib5) 2007; 39
Prakash, Kamel, Gummerus, Wilner (bib7) 1997; 25
Robison, Jacobs (bib8) 2009; 1
Anderson, Luffer-Atlas, Knadler (bib1) 2009; 22
Wynalda, Hauer, Wienkers (bib11) 2000; 28
Slatter, Stalker, Feenstra, Welshman, Bruss, Sams, Johnson, Sanders, Hauer, Fagerness (bib9) 2001; 29
Khetani, Bhatia (bib6) 2008; 26
Guillouzo, Guguen-Guillouzo (bib4) 2008; 4
Dalvie, Obach, Kang, Prakash, Loi, Hurst, Nedderman, Goulet, Smith, Bu (bib3) 2009; 22
Khetani (10.1124/dmd.110.034876_bib6) 2008; 26
Robison (10.1124/dmd.110.034876_bib8) 2009; 1
Slatter (10.1124/dmd.110.034876_bib9) 2001; 29
Smith (10.1124/dmd.110.034876_bib10) 2009; 22
Prakash (10.1124/dmd.110.034876_bib7) 1997; 25
Guillouzo (10.1124/dmd.110.034876_bib4) 2008; 4
Wynalda (10.1124/dmd.110.034876_bib11) 2000; 28
Atrakchi (10.1124/dmd.110.034876_bib2) 2009; 22
Hewitt (10.1124/dmd.110.034876_bib5) 2007; 39
Dalvie (10.1124/dmd.110.034876_bib3) 2009; 22
Anderson (10.1124/dmd.110.034876_bib1) 2009; 22
References_xml – volume: 1
  start-page: 1193
  year: 2009
  end-page: 1200
  ident: bib8
  article-title: Metabolites in safety testing
  publication-title: Bioanalysis
– volume: 22
  start-page: 267
  year: 2009
  end-page: 279
  ident: bib10
  article-title: Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment
  publication-title: Chem Res Toxicol
– volume: 26
  start-page: 120
  year: 2008
  end-page: 126
  ident: bib6
  article-title: Microscale culture of human liver cells for drug development
  publication-title: Nat Biotechnol
– volume: 25
  start-page: 863
  year: 1997
  end-page: 872
  ident: bib7
  article-title: Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans
  publication-title: Drug Metab Dispos
– volume: 28
  start-page: 1014
  year: 2000
  end-page: 1017
  ident: bib11
  article-title: Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes
  publication-title: Drug Metab Dispos
– volume: 22
  start-page: 243
  year: 2009
  end-page: 256
  ident: bib1
  article-title: Predicting circulating human metabolites: how good are we?
  publication-title: Chem Res Toxicol
– volume: 4
  start-page: 1279
  year: 2008
  end-page: 1294
  ident: bib4
  article-title: Evolving concepts in liver tissue modeling and implications for in vitro toxicology
  publication-title: Expert Opin. Drug Metab Toxicol
– volume: 22
  start-page: 357
  year: 2009
  end-page: 368
  ident: bib3
  article-title: Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites
  publication-title: Chem Res Toxicol
– volume: 29
  start-page: 1136
  year: 2001
  end-page: 1145
  ident: bib9
  article-title: Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [
  publication-title: Drug Metab Dispos
– volume: 39
  start-page: 159
  year: 2007
  end-page: 234
  ident: bib5
  article-title: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies
  publication-title: Drug Metab Rev
– volume: 22
  start-page: 1217
  year: 2009
  end-page: 1220
  ident: bib2
  article-title: Interpretation and considerations on the safety evaluation of human drug metabolites
  publication-title: Chem Res Toxicol
– volume: 25
  start-page: 863
  year: 1997
  ident: 10.1124/dmd.110.034876_bib7
  article-title: Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans
  publication-title: Drug Metab Dispos
– volume: 22
  start-page: 357
  year: 2009
  ident: 10.1124/dmd.110.034876_bib3
  article-title: Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites
  publication-title: Chem Res Toxicol
  doi: 10.1021/tx8004357
– volume: 22
  start-page: 1217
  year: 2009
  ident: 10.1124/dmd.110.034876_bib2
  article-title: Interpretation and considerations on the safety evaluation of human drug metabolites
  publication-title: Chem Res Toxicol
  doi: 10.1021/tx900124j
– volume: 22
  start-page: 267
  year: 2009
  ident: 10.1124/dmd.110.034876_bib10
  article-title: Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment
  publication-title: Chem Res Toxicol
  doi: 10.1021/tx800415j
– volume: 1
  start-page: 1193
  year: 2009
  ident: 10.1124/dmd.110.034876_bib8
  article-title: Metabolites in safety testing
  publication-title: Bioanalysis
  doi: 10.4155/bio.09.98
– volume: 29
  start-page: 1136
  year: 2001
  ident: 10.1124/dmd.110.034876_bib9
  article-title: Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects
  publication-title: Drug Metab Dispos
– volume: 4
  start-page: 1279
  year: 2008
  ident: 10.1124/dmd.110.034876_bib4
  article-title: Evolving concepts in liver tissue modeling and implications for in vitro toxicology
  publication-title: Expert Opin. Drug Metab Toxicol
  doi: 10.1517/17425255.4.10.1279
– volume: 22
  start-page: 243
  year: 2009
  ident: 10.1124/dmd.110.034876_bib1
  article-title: Predicting circulating human metabolites: how good are we?
  publication-title: Chem Res Toxicol
  doi: 10.1021/tx8004086
– volume: 39
  start-page: 159
  year: 2007
  ident: 10.1124/dmd.110.034876_bib5
  article-title: Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies
  publication-title: Drug Metab Rev
  doi: 10.1080/03602530601093489
– volume: 28
  start-page: 1014
  year: 2000
  ident: 10.1124/dmd.110.034876_bib11
  article-title: Oxidation of the novel oxazolidinone antibiotic linezolid in human liver microsomes
  publication-title: Drug Metab Dispos
  doi: 10.1016/S0090-9556(24)15179-3
– volume: 26
  start-page: 120
  year: 2008
  ident: 10.1124/dmd.110.034876_bib6
  article-title: Microscale culture of human liver cells for drug development
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt1361
SSID ssj0014439
Score 2.3565054
Snippet Metabolism is one of the important determinants of the overall disposition of drugs, and the profile of metabolites can have an impact on efficacy and safety....
SourceID proquest
pubmed
pascalfrancis
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1900
SubjectTerms Biological and medical sciences
Cells, Cultured
Chromatography, High Pressure Liquid
Coculture Techniques - methods
Cryopreservation
Hepatocytes - metabolism
Humans
Medical sciences
Metabolic Detoxication, Phase I
Metabolic Detoxication, Phase II
Models, Biological
Molecular Structure
Pharmaceutical Preparations - chemistry
Pharmaceutical Preparations - metabolism
Pharmacology. Drug treatments
Predictive Value of Tests
Tandem Mass Spectrometry
Title Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites
URI https://dx.doi.org/10.1124/dmd.110.034876
https://www.ncbi.nlm.nih.gov/pubmed/20595376
https://www.proquest.com/docview/755163293
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLay7mXSNO3e7FL5YeoeUjqCCeDHqGVLFiXaJVG6viADpurUQpQQaZ20v7vfsWNsjDMl2kWKkMGAA-fD5xyfG0KviJPFMOnBh8QC13I9xiyaEN_KOO85IF7QoLKYjifeYOa-P-udtVo_Da-ldRkfJ9-3xpX8D1XhGNBVRMn-A2X1TeEAtIG-sAUKw_avaNzXaTVlmONYeNctqoyZMHsCS4F2kdyUojSdTLHBVYpyIXLKjNOlKD70tViq5fzwG4iRleFdrKifXC6Tqr5XftE5Xa4vOmNeAmpE3PLKFGurvmvVp6pupJfaI0zP_OEQfp15XwZKzXme6hX90SCc9idDuUp9VVkWdNen8y_n4fzzSPaWLNFXnc6G7yb9ifbOV0Wk1TKGcAmxN1xCavuU6az6ocneLZ86NKseTJsANXNd06a2RXsyW3k9xZPAhLJtTNggD9kG84fd3nbG4riAhvQ6FXETxzYBPW9LBu_fOKv2dwSxFdQ6j9xCtx1QZ0SljdHHxtrlukSqaeqvq-SiMOabzRF3CU93F2wFn3Qma7HsVpYqoWl6H91T2g7uS-g-QC2eP0SH6oXfHGHz5R7hQ2yS4hH60eAbFxlmeBPfuME31vjGEt-4LHCNb1zhG1f4xhrfGCiNDXxjgWFs4Psxmr0NpycDS5ULsRLi0dLiQUpJynzCKegAaRd4sZ-I-rOsC4AjceKkpJsEAQUuliYZ9eM4yyhP7Mx2mRcE5Anay4uc7yMc-CmNY-KD7pG6jGUxEYk04VyaZl5GSBtZNR2iROXSFyVdrqJKp3bcCOgGDTuSdGuj1_r8hcwis_PMbk3WSMnAUraNAIk7rznYoL8eooZdG-EaEBFwD2ESZDkv1qvIF3ZyAiJ_Gz2VQGkuhocXuZ6e_enuz9Gd5oN-gfbK5Zq_BEm9jA8qmP8Ccj_u0g
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+a+Micropatterned+Hepatocyte+Coculture+System+to+Generate+Major+Human+Excretory+and+Circulating+Drug+Metabolites&rft.jtitle=Drug+metabolism+and+disposition&rft.au=WEIWEI+WANG%2C+Wendy&rft.au=KHETANI%2C+Salman+R&rft.au=KRZYZEWSKI%2C+Stacy&rft.au=DUIGNAN%2C+David+B&rft.date=2010-10-01&rft.pub=American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.volume=38&rft.issue=10&rft.spage=1900&rft.epage=1905&rft_id=info:doi/10.1124%2Fdmd.110.034876&rft.externalDBID=n%2Fa&rft.externalDocID=23276863
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon